BEBT 508
Alternative Names: BEBT-508Latest Information Update: 03 Apr 2023
At a glance
- Originator BeBetter Med
- Class Hepatoprotectants; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
Most Recent Events
- 03 Apr 2023 Early research in Non-alcoholic fatty liver disease in China (unspecified route) before April 2023 (BeBetter Med pipeline, April 2023)
- 03 Apr 2023 Early research in Non-alcoholic steatohepatitis in China (unspecified route) before April 2023 (BeBetter Med pipeline, April 2023)
- 20 Dec 2021 Guangzhou BeBetter Medicine Technology is now called BeBetter Med